Ash 2020 – hints of durability emerge for Uniqure's gene therapy
And bleeds seen with the “transformative” project were played down.
Ash 2020 – durability worries hit Sangamo and Pfizer’s haemophilia A gene therapy
Waning factor VIII levels with giroctocogene fitelparvovec once again raise the spectre of Biomarin’s valrox.
Ash 2020 – Forma gets an early edge over Agios in sickle cell disease
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Ash 2020 – IGM averts disaster, but competition looms
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
Ash 2020 – UK biotech's hollow victory
Results with Loxo-305 could justify Lilly’s acquisition of Loxo, but its inventor, the UK’s Redx, can just read ‘em and weep.
Ash 2020 – Syros sets out a path to market
With funding in place, Syros is pushing its lead leukaemia project into pivotal development, and has a newly acquired second asset not far behind.
Ash 2020 – multiple myeloma goes beyond BCMA
While projects against BCMA abound, two little-known multiple myeloma targets make bids for attention at Ash.
Ash 2020 – efficacy and deaths mark the Car-T multiple myeloma race
The latest showing from Car-T players in multiple myeloma sees Johnson & Johnson beat Bluebird, but toxicity hangs over both.
Ash 2020 – Crispr gets another boost
Data in three more patients support Crispr and Vertex’s hope of developing a functional cure for beta-thalassaemia and sickle cell disease.
